Liposomal amphotericin b for treatment of leishmaniasis: from the identification of critical physicochemical attributes to the design of effective topical and oral formulations
Carregando...
Data
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Federal de Minas Gerais
Descrição
Tipo
Artigo de periódico
Título alternativo
Primeiro orientador
Membros da banca
Resumo
The liposomal amphotericin B (AmB) formulation, AmBisome®, still represents the best
therapeutic option for cutaneous and visceral leishmaniasis. However, its clinical efficacy depends
on the patient’s immunological status, the clinical manifestation and the endemic region. Moreover,
the need for parenteral administration, its side effects and high cost significantly limit its use in
developing countries. This review reports the progress achieved thus far toward the understanding
of the mechanism responsible for the reduced toxicity of liposomal AmB formulations and the
factors that influence their efficacy against leishmaniasis. It also presents the recent advances in the
development of more effective liposomal AmB formulations, including topical and oral liposome
formulations. The critical role of the AmB aggregation state and release rate in the reduction of drug
toxicity and in the drug efficacy by non-invasive routes is emphasized. This paper is expected to
guide future research and development of innovative liposomal formulations of AmB.
Abstract
Assunto
Lipossomos, Anfotericina B, Anfotericina B, Leishmaniose, Vias de administração de medicamentos
Palavras-chave
liposomes, Amphotericin B, Leishmaniasis, Oral route, PEGylation, Topical route
Citação
Curso
Endereço externo
https://www.mdpi.com/1999-4923/15/1/99